Monument Therapeutics Secures US Patent for Breakthrough Schizophrenia Treatment

Cambridge, Thursday, 30 April 2026.
Monument Therapeutics has secured US patent exclusivity through 2042 for MT1988. This pioneering treatment utilizes digital biomarkers to uniquely target and treat cognitive impairment associated with schizophrenia.